REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 447.50
Bid: 440.00
Ask: 455.00
Change: -2.50 (-0.56%)
Spread: 15.00 (3.409%)
Open: 450.00
High: 450.00
Low: 447.50
Prev. Close: 450.00
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK and EU regulatory approval update

26 Feb 2024 07:00

RNS Number : 3374E
Tristel PLC
26 February 2024
 

TRISTEL plc

("Tristel", the "Company", or the "Group")

 

UK and EU regulatory approval update for surface disinfection system

 

Sustainable alternative to commonly used pre-wetted plastic wipes to become available in Europe

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, announces that all reviews under the Medical Devices Regulation 2002 ("UK MDR") and the European Union Medical Device Regulation 2017/745 ("EU MDR") for approval of the Company's TANK ClO? Sporicidal Disinfectant system have been successfully concluded and a positive recommendation for UKCA and MDR certification has been made.

 

The TANK system and accompanying capsules are the newest additions to the Cache range, which provides sporicidal surface disinfection in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Following MDR approvals Tristel will be able to accelerate sales activity for this product throughout Europe and across geographies that recognise the high standard of safety and quality demonstrated by products conforming to the new EU MDR. The Directors believe that approval, will give Tristel the opportunity to deliver significant growth in sales of the Cache product range going forward, targeting a largely untapped sporicidal surface disinfection market. The Company expects to officially launch these latest products in Europe before the current financial year end on 30 June 2024.

 

For the year ended 30 June 2023 revenues from the Cache range totalled £3.3m, representing 9.2% of total annual turnover.

 

About TANK ClO? Sporicidal Disinfectant and the Cache range (https://thecachecollection.com)

TANK ClO? Sporicidal Disinfectant is a storage and distribution system powered by ClO? sporicidal disinfectant capsules. One TANK ClO? Sporicidal Disinfectant capsule makes 10 litres of sporicidal solution, which is the same as 2,000 sporicidal wipes wetted with 5ml of liquid. Rather than relying on convenience products that do harm once they are disposed of, TANK uses plastic thoughtfully. The core components are reusable, and all the plastic items within the system are recyclable. Users can apply TANK ClO? Sporicidal Disinfectant working solution with a Doser, Foamer or Sprayer, and reduce plastic waste by pairing TANK working solution with any dry wipe.

 

 

The TANK ClO? Sporicidal Disinfectant system

 

 

The broader Cache product range for sporicidal surface disinfection

 

For further information on the TANK ClO? Sporicidal Disinfectant system please view the product brochure here:

https://thecachecollection.com/wp-content/uploads/2021/09/Mkt-Bro-1508-6-TANK-ClO2-Sporicidal-Brochure-EN.pdf

 

Paul Swinney, CEO of Tristel, commented: "Whilst our Cache product range is intended for environmental surfaces, many of the surfaces in a hospital setting are considered medical devices and so it is key for any disinfection products to comply with the new EU Medical Device Regulation. It is a very significant achievement to have concluded all reviews successfully and we expect to receive our recommendation for certification from our Notified Body very shortly. Conformity with MDR will allow us to apply CE marking to these new products and gives us the opportunity to deliver significant growth in sales of the Cache product range going forward."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Charlotte Edgar

Mob: 07884 664 686

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAGZGZZNFRGDZM
Date   Source Headline
20th Mar 20204:43 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:37 pmRNSPrice Monitoring Extension
13th Mar 20204:14 pmRNSIssue of Equity
10th Mar 202011:56 amRNSIssue of Equity
6th Mar 20201:42 pmRNSHolding(s) in Company
3rd Mar 202010:24 amRNSDirector/PDMR Shareholding and Issue of Equity
26th Feb 20207:00 amRNSHolding(s) in Company
25th Feb 20209:06 amRNSDirector/PDMR Shareholding (Replacement)
25th Feb 20207:00 amRNSDirector/PDMR Shareholding
24th Feb 20207:00 amRNSHalf-year Report
20th Feb 202011:12 amRNSIssue of Equity
18th Feb 20209:51 amRNSIssue of Equity
30th Jan 20203:43 pmRNSIssue of Equity
15th Jan 20207:00 amRNSInvestor results presentation
14th Jan 20201:09 pmRNSIssue of Equity
17th Dec 201911:01 amRNSResult of AGM
17th Dec 20197:00 amRNSAGM Statement and notice of results
4th Dec 20199:30 amRNSIssue of Equity
3rd Dec 201911:20 amRNSHolding(s) in Company
26th Nov 20197:00 amRNSForthcoming Appointment of Non-Executive Chairman
20th Nov 201910:08 amRNSIssue of Equity
18th Nov 20197:00 amRNSUpdate on MobileODT strategic investment
1st Nov 20194:00 pmRNSAudited accounts and notice of AGM
30th Oct 20192:25 pmRNSIssue of Equity
16th Oct 20197:00 amRNSFinal Results
14th Oct 201911:43 amRNSIssue of Equity
13th Sep 20193:58 pmRNSIssue of Equity
10th Sep 201910:27 amRNSHolding(s) in Company
28th Aug 20197:00 amRNSIssue of Equity
21st Aug 20197:00 amRNSInvestor results presentation
7th Aug 201910:31 amRNSIssue of Equity
31st Jul 20193:45 pmRNSHolding(s) in Company
22nd Jul 20197:00 amRNSTrading update, Acquisition & Notice of Results
12th Jun 20197:00 amRNSIssue of Equity
5th Jun 20197:00 amRNSShareholder Open Day
17th May 20191:58 pmRNSIssue of Equity
10th May 201910:26 amRNSHolding(s) in Company
1st Apr 20197:00 amRNSRegulatory approvals in China and South Korea
26th Mar 20197:00 amRNSHolding(s) in Company
6th Mar 20197:00 amRNSIssue of Equity
4th Mar 20192:31 pmRNSIssue of Equity and PDMR Dealing
1st Mar 20193:42 pmRNSDirector/PDMR Shareholding
25th Feb 20197:00 amRNSHalf-year Report
5th Feb 20197:00 amRNSDirector Appointment
14th Jan 20195:26 pmRNSDirector/PDMR Shareholding
14th Jan 201912:00 pmRNSInvestor results presentation
11th Dec 201810:49 amRNSResult of AGM
11th Dec 20187:00 amRNSAGM Statement and notice of results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.